Riskpilot← Back to searchSign inGet full accessPHARMAVEST ApS
APSActiveCVR 26385180Naverland 22Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20021 employees
Revenue 2024
DKK 1,9M
-2% vs 2023
EBITDA margin
17.9%
-70% vs 2023
Equity ratio
77.7%
Financial strength
Net profit 2024
DKK 271K
-73% vs 2023
| Revenue | DKK 1,9M | -2% |
| EBITDA | DKK 345K | -70% |
| Net profit | DKK 271K | -73% |
| Total assets | DKK 7,1M | +4% |
| Equity | DKK 5,5M | -4% |
| Employees | 1 | — |
Legal name
PHARMAVEST ApS
CVR number
26385180
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. januar 2002
Share capital
DKK 500.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive virksomhed med køb og salg af medicinalprodukter og anden hermed beslægtet virksomhed.
Address
Naverland 22
Phone
+4570251117
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.642 | 1.435 | 926 | 822 | 479 | 338 | 1.085 | 1.771 | 1.159 | 1.762 | 1.771 | 1.975 | 1.926 |
| Staff expenses | -656 | -883 | -670 | -681 | -514 | -557 | -521 | -517 | -612 | -692 | -691 | -819 | -1.301 |
| EBITDA | 986 | 552 | 257 | 141 | -35 | -218 | 552 | 1.254 | 547 | 1.070 | 1.080 | 1.156 | 345 |
| Depreciation & amort. | -19 | -13 | -4 | -67 | -86 | -105 | -79 | -112 | -83 | -78 | -45 | -43 | -126 |
| EBIT | 968 | 539 | 253 | 74 | -121 | -324 | 473 | 1.142 | 464 | 992 | 1.034 | 1.114 | 219 |
| Net financials | 13 | 13 | 13 | 1 | -3 | -0 | -1 | -70 | -80 | -154 | -155 | 174 | 133 |
| Profit before tax | 981 | 552 | 265 | 75 | -124 | -324 | 473 | 1.072 | 384 | 838 | 880 | 1.287 | 352 |
| Tax | 244 | 137 | 65 | 19 | -30 | -63 | 112 | 254 | 102 | 220 | 199 | 274 | 81 |
| Net profit | 737 | 416 | 200 | 57 | -94 | -261 | 360 | 818 | 281 | 618 | 680 | 1.013 | 271 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3.637 | 3.402 | 3.540 | 3.736 | 3.881 | 3.223 | 3.733 | 4.319 | 5.192 | 5.293 | 6.042 | 6.838 | 7.099 |
| Equity | 2.907 | 2.803 | 2.883 | 2.940 | 2.845 | 2.585 | 2.945 | 3.643 | 3.804 | 4.302 | 4.857 | 5.746 | 5.517 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 729 | 599 | 657 | 793 | 1.035 | 639 | 781 | 676 | 1.388 | 991 | 1.152 | 1.045 | 1.582 |
| Total debt | 729 | 599 | 657 | 793 | 1.035 | 639 | 781 | 676 | 1.388 | 991 | 1.152 | 1.045 | 1.582 |
EBITDA margin
17.9%
This company
15.8%
Market median
+13% vs market
20122024
Equity ratio
77.7%
This company
38.2%
Market median
+103% vs market
20122024
Return on equity
4.9%
This company
18.4%
Market median
-73% vs market
20122024
Net profit margin
14.1%
This company
8.1%
Market median
+74% vs market
20122024
Asset turnover
0.27×
This company
1.12×
Market median
-76% vs market
20122024
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PB Management | Management | 2002 | — | — |
RL Management | Management | 2002 | — | — |
FO Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
HA Audit | Audit | 2002 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Chairman | 2015 | — | — | |
| Board of Directors | 2015 | — | — | |
UY | Board of Directors | 2015 | — | — |
| Board of Directors | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FRANK LYDIG HOLDING ApS | Company | 100.0% | 100.0% | 2017 |
LYDIG ApS | Company | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FRANK LYDIG HOLDING ApS
PHARMAVEST ApS Board members of PHARMAVEST ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Preben Bang Henriksen | Management | 0 companies |
| Regner Lydig Kristensen | Management | 0 companies |
| Frank Orluff Lydig Kristensen | Chief Executive Officer | 0 companies |
| Harry Aamann | Audit | 0 companies |
| Niels Christian Schou | Chairman | 0 companies |
| Torben Vilsgaard | Chairman | 0 companies |
| Anders Nicolai Petri | Board of Directors | 0 companies |
| Ulla Yde | Board of Directors | 0 companies |
| Aage Madsen | Board of Directors | 0 companies |